FK 906: an orally active human renin inhibitor; used for the long-term treatment of patients with essential hypertension; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 132922 |
| MeSH ID | M0221003 |
| Synonym |
|---|
| 1-cyclohexyl-3-hydroxy-6-methyl-2-(n(alpha)-methyl-n(alpha)-(2-(n-methyl-n-(2-(n-methyl-n-morpholinocarbonylamino)ethyl)aminocarbonyloxy)-3-phenylpropionyl)histidyl)aminoheptane hydrochloride |
| 150679-23-5 |
| fk 906 |
| 8-benzyl-n-(1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl)-11-[(1h-imidazol-5-yl)methyl]-2,5,10-trimethyl-1-(morpholin-4-yl)-1,6,9-trioxo-7-oxa-2,5,10-triazadodecan-12-imidic acid--hydrogen chloride (1/1) |
| DTXSID90934027 |
| [1-[[(2s)-1-[(1-cyclohexyl-3-hydroxy-6-methylheptan-2-yl)amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl] n-methyl-n-[2-[methyl(morpholine-4-carbonyl)amino]ethyl]carbamate;hydrochloride |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||